What makes YK-11 unique?

YK-11 is the only SARM with a dual mechanism: it's both a SARM AND a myostatin inhibitor. It works by inducing follistatin, which blocks myostatin (the protein that limits muscle growth). This gives it theoretical advantages over pure SARMs.

What research data exists for YK-11?

Extremely limited. Only cell culture (in vitro) studies exist. NO animal trials and NO human clinical trials have been published. All 'research' data comes from cell studies or anecdotal user reports.

Dual Mechanism • Cell Studies Only • Steroidal SARM

YK-11: The Myostatin Inhibitor SARM

By MeetPeptide Research Team

Unique dual mechanism: SARM + myostatin inhibitor via follistatin induction. Only cell study data exists — NO animal or human trials published. Steroidal structure from DHT raises hepatotoxicity concerns. Here's what's known.

Common Research Dose
(Daily)

Human Trial Data
(None Published)

Mechanism
SARM + Myostatin

⚠️ WARNING: No Human Data

YK-11 has ZERO published animal or human trials. Only cell culture (in vitro) studies exist. All "data" you see is either cell study results or anecdotal user reports. It is NOT a well-researched compound.

All SARMs are banned by WADA. Not FDA approved. This page is for educational purposes only.

NO HUMAN TRIALS WADA BANNED

Mechanism

How YK-11 Works

Unique dual mechanism: partial SARM agonist + follistatin inducer (myostatin inhibitor). Steroidal structure from DHT differentiates it from non-steroidal SARMs.

🧬

Dual SARM + Myostatin Inhibitor

Induces follistatin expression in muscle cells, which blocks myostatin (the muscle growth inhibitor). This dual action theoretically provides more muscle-building potential than pure SARMs.

🧪

Cell Study Data Only

ALL published research is in vitro (cell culture). No animal studies, no human trials. Everything else is anecdotal. Claims about YK-11's effects have no controlled research backing.

🧬

Steroidal Structure (DHT Derivative)

Unlike non-steroidal SARMs (Ostarine, LGD-4033), YK-11 is a steroidal SARM derived from DHT. This raises additional concerns about 5-alpha-reduced metabolites and hepatotoxicity.

🎯

Partial AR Agonist

As a SARM, binds androgen receptors in muscle. However, as a steroidal compound, may also convert to DHT-like metabolites with traditional steroid side effect profile.

Safety

Side Effects & Risks

⚠️ Major Concerns

ZERO animal/human safety data
Unknown hepatotoxicity (steroidal structure)
May have traditional steroid side effects
5-alpha-reduced metabolites possible
No quality control on research chemicals

Other Risks

Significant testosterone suppression likely
Water retention possible
Hair loss risk (steroidal)
Acne and oiliness
Unknown long-term effects

Bottom Line

Key Takeaways

✅ What We Know

Unique dual mechanism (SARM + myostatin)
Cell studies show follistatin induction

⚠️ What We DON'T Know

ANY animal trial data
ANY human trial data
Safety at ANY dose
Long-term effects
Actual muscle-building potential

🔬 Verified Research Source

Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.

🧬 YK-11 Buy from Swiss Chems — Lab-tested, verified purity → Shop Now

Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.

⚠️ Disclaimer

Educational only. YK-11 has NO human or animal trial data. Only cell studies exist. Not FDA approved. Banned by WADA. Consult healthcare provider.

YK-11: The Myostatin Inhibitor SARM

How YK-11 Works

Side Effects & Risks

Key Takeaways

🔬 Verified Research Source

🛒 Recommended Products

More SARM Research

Want the Complete Protocol Guide?